Skip to main content Back to Top
Advertisement

7/1/2020

Furosemide Injection

Products Affected - Description

    • Furosemide injection, AuroMedics, 10 mg/mL, 10 mL vial, 25 count, NDC 55150-0324-25
    • Furosemide injection, AuroMedics, 10 mg/mL, 2 mL vial, 25 count, NDC 55150-0322-25
    • Furosemide injection, AuroMedics, 10 mg/mL, 4 mL vial, 25 count, NDC 55150-0323-25
    • Furosemide injection, Pfizer, 10 mg/mL, 10 mL Luer Lock syringe, 10 count, NDC 00409-1639-10
    • Furosemide injection, Pfizer, 10 mg/mL, 4 mL syringe, 10 count, NDC 00409-9631-04

Reason for the Shortage

    • American Regent is not actively marketing furosemide injection.
    • Amneal discontinued furosemide injection.
    • AuroMedics has furosemide injection on shortage due to shipping delays.
    • Avet Pharmaceuticals has furosemide injection available.
    • Baxter had furosemide injection on shortage due to manufacturing delays and increased demand.
    • Fresenius Kabi had furosemide injection on shortage due to increased demand.
    • Pfizer had furosemide injection on shortage due to manufacturing delays and increased demand.

Available Products

    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 10 mL vial, 25 count, NDC 23155-0476-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 2 mL vial, 25 count, NDC 23155-0473-41
    • Furosemide injection, Avet Pharmaceuticals, 10 mg/mL, 4 mL vial, 25 count, NDC 23155-0474-41
    • Furosemide injection, Baxter, 10 mg/mL, 10 mL vial, 25 count, NDC 36000-0284-25
    • Furosemide injection, Baxter, 10 mg/mL, 2 mL vial, 25 count, NDC 36000-0282-25
    • Furosemide injection, Baxter, 10 mg/mL, 4 mL vial, 25 count, NDC 36000-0283-25
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 25 count, NDC 63323-0280-10
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0280-02
    • Furosemide injection, Fresenius Kabi, 10 mg/mL, 4 mL vial, 25 count, NDC 63323-0280-04
    • Furosemide injection, Pfizer, 10 mg/mL, 10 mL vial, 25 count, NDC 00409-6102-10
    • Furosemide injection, Pfizer, 10 mg/mL, 2 mL vial, 25 count, NDC 00409-6102-02
    • Furosemide injection, Pfizer, 10 mg/mL, 4 mL vial, 25 count, NDC 00409-6102-04

Estimated Resupply Dates

    • AuroMedics has furosemide 10 mg/mL 2 mL, 4 mL, and 10 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Pfizer has furosemide 10 mg/mL 4 mL syringes available in limited supply. There are short-dated 10 mL syringes available with an expiration date of October 2020.

Updated

Updated July 1, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 19, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.